Law360, Los Angeles (February 22, 2016, 10:39 PM EST) -- Warner Chilcott will have to face claims it paid drugmakers to delay producing a generic version of its contraceptive Loestrin in multidistrict litigation after the First Circuit on Monday found that noncash settlements can be subject to antitrust scrutiny.
Wholesalers, end payors and others alleged that Warner Chilcott Co.'s agreement with Watson Pharmaceuticals Inc. — both of which are now owned by Actavis Inc. — and another with Lupin Pharmaceuticals Inc. amounted to a scheme to keep generic versions of the drug out of the market.
U.S. District Judge William E. Smith in September 2014 tossed their claims, saying that under...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!